Danish allergy immunotherapy specialist ALK Abello has announced that EURneffy 2mg nasal adrenaline spray, the UK’s first ...

US biotech Exelixis has announced detailed results from STELLAR-303, a global Phase III pivotal trial evaluating ...

New data from the FLUNITY-HD study, published on October 17 in The Lancet, demonstrated that Sanofi's Efluelda known as Fluzone High-Dose in North America) significantly reduced the risk of ...

Swedish Orphan Biovitrum, the Nordic biotech company also known as Sobi, today announced positive third-quarter 2025 ...

San Diego-based Rani Therapeutics Holdings, a biotherapeutics company focused on the oral delivery of biologics and drugs, ...

In October 2025, Pelage completed a $120 million Series B financing, co-led by ARCH Venture Partners and GV (Google Ventures) ...

The US Food and Drug Administration (FDA) has accepted for expedited review French pharma major Sanofi’s supplemental ...

In 2014, I sat in a room at a “Genetic Networks” conference listening to Brendan Frey present his talk titled Decoding the ...

Mosaic Therapeutics has named Thomas Fuchs as chief executive to lead the Cambridge-based oncology biotech through its transition into clinical development and a planned series B fundraising round. He ...

The US Food and Drug Administration (FDA) has approved Rybelsus (oral semaglutide) for reducing the risk of major adverse ...

UK biotech Cyclana Bio has secured £5 million ($6.1 million) in pre-seed funding to advance its platform targeting women’s ...

Swiss pharma giant Novartis yesterday presented positive new Pluvicto (lutetium (177Lu) vipivotide tetraxetan) data from the ...